Hunan Mabgeek Biotechnology Co., Ltd. (hereinafter referred to as Mabgeek Biotechnology) was established in 2016. It mainly focuses on the unmet clinical needs in the fields of allergic inflammatory diseases and autoimmune diseases, and conducts independent research and development and commercialization of innovative antibody drugs through differentiated competitive strategies. The core technical team led by Dr. Zhang Chenghai, the founder of Mabgeek Biotechnology, has presided over the research and development and clinical application of more than ten innovative antibody drugs. Currently, five innovative antibody drugs are in various stages of clinical research. 

Through years of extreme innovation, the Mabgeek team has created the TEADA antibody discovery platform, which can screen out candidate molecules with high biological activity and good drugability at an extremely high efficiency. 

After more than seven years of rapid development, Mabgeek Biotech has initially established a rich R&D pipeline. Its first self-developed long-acting antibody drug targeting IL-4Rα, MG-K10, is currently undergoing Phase III clinical trials for moderate to severe atopic dermatitis (AD). The Phase III clinical trial for moderate to severe asthma is planned to start in the second half of 2024. 

Existing Phase II clinical data show that MG-K10 significantly improves the clinical symptoms of patients with moderate to severe AD and moderate to severe asthma, with good safety and support for administration every four weeks. MG-K10 not only extends the dosing interval but also demonstrates best-in-class response from biomarkers to efficacy in different indications, with prominent clinical advantages. Development is being carried out simultaneously in Europe and the United States. 

MG-K10 is the only long-acting anti-IL-4Rα antibody candidate drug that has been clinically verified among those currently on the market and in clinical development. It is expected to achieve better therapeutic responses, longer dosing intervals, and lower medication costs, enhance patient compliance, and better achieve long-term disease control. 

Team Experience

A complete and well-honed R&D team with years of collaboration, covering the entire chain of innovative antibody molecule discovery research;

The team has over 10 years of experience in developing monoclonal antibody biosimilars and 5 years of experience in developing innovative antibody new drugs;

R&D Team: All team members come from well-known domestic pharmaceutical companies, and the team has over 8 years of cooperation experience;

Research Platforms: Including molecular construction and protein expression and purification platform, hybridoma screening platform, pharmacological and pharmacodynamic analysis platform, humanization platform, large molecule drug analysis platform, and cell line development platform;

R&D Experience: The developed drug molecules cover areas such as oncology, autoimmune diseases, and ophthalmic diseases.